| Identification | Back Directory | [Name]
Benzoic acid, 2-[[5-fluoro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-, hydrazide | [CAS]
2764609-97-2 | [Synonyms]
RSH-7
Benzoic acid, 2-[[5-fluoro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-, hydrazide | [Molecular Formula]
C22H25FN8O | [MOL File]
2764609-97-2.mol | [Molecular Weight]
436.49 |
| Hazard Information | Back Directory | [Uses]
RSH-7 is a potent BTK and FLT3 inhibitor with IC50s of 47, 12 nM, respectively. RSH-7 induces apoptosis and shows antiproliferative activities. RSH-7 inhibits BTK and FLT3 signaling and shows anti-tumor activity[1]. | [in vivo]
RSH-7 (25, 50 mg/kg; i.p.; daily for 16 days) shows anti-tumor activity with significantly and dose-dependently suppresses the tumor growth in mouse[1]. | Animal Model: | Female NOD/SCID mice (jeko-1 cell-inoculated xenograft NOD/SCID mice models)[1] | | Dosage: | 25, 50 mg/kg | | Administration: | I.p.; daily for 16 days | | Result: | Suppressed tumor growth in a dose-dependent manner, with tumor growth inhibition (TGI) values of 66.95% and 79.78% at doses of 25 and 50 mg/kg, |
| Animal Model: | Female NOD/SCID mice (MV4-11 cell-inoculated xenograft NOD/SCID mice models)[1] | | Dosage: | 10, 20 mg/kg | | Administration: | I.p.; daily for 21 days | | Result: | Significantly and dose-dependently suppressed the tumor growth with the TGI rates of 74.23% and 94.84% at the dosage of 10 and 20 mg/kg, respectively. |
| [References]
[1] Ran F, et al. Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114913. DOI:10.1016/j.ejmech.2022.114913 |
|
|